Plus Therapeutics (PSTV) Free Cash Flow (2016 - 2025)
Plus Therapeutics has reported Free Cash Flow over the past 16 years, most recently at -$6.3 million for Q4 2025.
- Quarterly Free Cash Flow fell 415.96% to -$6.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$20.8 million through Dec 2025, down 94.79% year-over-year, with the annual reading at -$20.8 million for FY2025, 94.79% down from the prior year.
- Free Cash Flow was -$6.3 million for Q4 2025 at Plus Therapeutics, down from -$2.6 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$1.2 million in Q4 2024 and troughed at -$6.3 million in Q4 2025.
- The 5-year median for Free Cash Flow is -$3.1 million (2021), against an average of -$3.6 million.
- Year-over-year, Free Cash Flow soared 55.86% in 2024 and then crashed 415.96% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$3.1 million in 2021, then rose by 23.56% to -$2.4 million in 2022, then rose by 18.59% to -$1.9 million in 2023, then soared by 36.45% to -$1.2 million in 2024, then crashed by 415.96% to -$6.3 million in 2025.
- Per Business Quant, the three most recent readings for PSTV's Free Cash Flow are -$6.3 million (Q4 2025), -$2.6 million (Q3 2025), and -$5.8 million (Q2 2025).